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ABSTRACT 
Objectives: Foot orthoses are commonly prescribed as an intervention for people with rheumatoid 
arthritis. The aim was to evaluate the clinical and cost analysis of two foot orthoses in people with 
established rheumatoid arthritis. 
Methodology: A single-blind randomised controlled trial was undertaken to compare customised 
foot orthoses and simple insoles in 41 people with established rheumatoid arthritis. The Foot 
Function Index measured foot pain, disability and functional limitation. Costs were estimated from 
the perspective of the NHS and from the societal (patient and family) perspective to include costs 
from outside the NHS.  Effects were assessed in terms of health gain expressed as quality adjusted 
life years (QALYS). 
Results: At baseline, 20 participants received the customised foot orthoses and 21 participants 
received a simple insole. After 16 weeks foot pain improved for both the custom-made foot orthoses 
(p=0.000) and simple insoles (p<0.01). Custom-made foot orthoses improved disability scores 
(p<0.001) but not for simple insoles (p=0.40). The cost effectiveness results demonstrated no 
difference in cost between the arms (custom-made foot orthoses: £159.10; simple insole: £79.10 
p=0.35), with the customised foot orthoses being less effective in terms of cost per QALY gain 
(p<0.001).  
Conclusions: In people with established RA, semi-rigid customised foot orthoses can improve pain 
and disability scores in comparison to simple insoles. From a cost effectiveness analysis perspective 
the customised foot orthoses were far more expensive to manufacture, with no significant cost per 
QALY gain.  
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INTRODUCTION 
Rheumatoid arthritis (RA) can lead to rapid development of joint damage and significant long-term 
disability [1]. Over 75% of RA patients report foot involvement within four years of diagnosis, and 
the reported prevalence of foot problems is as high as 50–90% [2-5]. Progressive joint destruction 
leads to varying degrees of physical disability with over 70% of all individuals with RA reporting 
moderate to severe foot pain, exposing a significant clinical challenge and an international public 
health priority [6].  
 
Clinically effective management of foot pain and prevention of foot deformity are the chief goals of 
intervention for people with RA [6,7]. Non-pharmacological interventions for RA that include foot 
orthoses and footwear can reduce pain and disability and improve long-term outcomes with existing 
and potential foot problems [8, 9]. Previous studies have reported on the clinical effectiveness of 
foot orthoses in people with established RA [10-13]. The National Institute for Clinical Effectiveness 
(NICE) reported the estimated annual cost of RA to be between £3.8 and £4.75 billion per year, 
including direct costs to the UK National Health Service (NHS) and other healthcare support agencies 
and indirect costs to the economy, including productivity losses and the personal impact on RA 
patients and their families [14]. Clark [15] reported that few studies have undertaken a cost 
effectiveness analysis to investigate the cost implication of the prescription of foot orthoses for 
people with foot pain and established RA, despite the high prevalence of foot involvement and the 
high direct cost of RA related health care to the UK economy. The issue of the cost effectiveness of 
providing foot orthoses in the NHS has been raised in chronic musculoskeletal foot conditions [16], 
as it represents a considerable burden to patients, clinicians and health providers. However, data 
relating to cost-effectiveness of the use of foot orthoses in people with RA are limited (17,18]. With 
such limited data the aim of this study was to evaluate the clinical and cost analysis of custom-made 
foot orthoses compared to simple insoles when prescribed for people with established RA. 
 
METHODOLOGY 
The research design was a single-blinded, exploratory randomised controlled clinical trial conducted 
over 16 weeks with participants randomly assigned to two intervention arms: custom-made foot 
orthoses (CMFO) or simple insoles (SI). The study design according to the CONSORT statement is 
demonstrated in Figure 1 [19]. Participants were recruited from a rheumatology outpatients 
department in the North-East of England, UK. Participants were eligible if they were over 18 years 
old, history of foot pain, ability to walk a required distance of 5m for measurement of foot function 
and had a diagnosis of RA according to the American College of Rheumatology/European League 
Against Rheumatism revised criteria [20]. Participants with a history of previous foot surgery or 
ulceration, those with an unstable medical regime or in a state of flare, currently using foot orthoses 
or unwilling to change their footwear to accommodate an orthotic, or with poor language ability or 
inability to understand the research protocol were excluded. Local ethical approval was obtained 
from Teesside University. All participants gave informed consent to participate in the study. The trial 
was registered with ANZCTR (ACTRN12615001252505). 
 
Sample size estimates for use in the study were calculated using sample size calculation tables [21]. 
For a large effect size (d) of 0.8, it was calculated that the trial would require 20 participants per arm 
to detect arm differences with 80% power.  A plan for allocating to either intervention arms was 
independently generated using randomisation software available from St George’s Hospital Medical 
School website, http://www.sgul.ac.uk/depts/chs/chs_research/stat_guide/guide.cfm. Participants 
were recruited by the primary researcher and once baseline data had been collected the primary 
researcher contacted the independent investigator for arm allocation. Participants were blinded to 
the intervention. 
 
Participants were randomly allocated to receive either CMFO or SI. The CMFO were manufactured 
from high density ethyl vinyl acetate, with a thickness of 20mm and a shore density of 50, a 
contoured medial arch, high heel cup and external medial posting correction customised to each 
patient according to the amount of valgus rearfoot deformity present and maximum forefoot 
balancing technique, determined by the external manufacturer providing the interventions (Langer 
Biomechanics Arm, Cheadle, UK). Both foot orthoses were covered with 1.6mm cushioning material 
extending the length of the foot. The SIs were a simple 6mm cushioning insole made from a 
breathable foam core on a rubber-silicone-ethylene compound, cut to fit the exact shape of the 
participants’ footwear. Both interventions used the same top colour.  
 
At the baseline visit age, sex, ethnicity, clinical characteristics and current pharmacological 
management were recorded.  Foot disease impact was measured using the Foot Function Index [22]. 
The Foot function Index is a self-administered questionnaire consisting of 23-items armed in three 
domains: foot pain (nine items), disability (nine items) and functional limitation (five items). Higher 
scores indicate greater pain, disability and limitation of activity and thus poorer foot health.  
PROCEDURE 
A neutral suspension plaster of Paris cast was taken of participant’s feet to enable provision of the 
CMFO. Participant’s footwear was evaluated to ensure footwear was suitable to accommodate 
either foot orthoses. A template was taken to determine shoe size. These activities were timed to 
aid in the evaluation of cost effectiveness and further information regarding cost effectiveness was 
collected. Randomisation allocation to either CFMO, made from the neutral suspension casts, or the 
SI, which were cut to fit the patients’ shoe was undertaken. To record weekly wear time and adverse 
events, which occurred during the 16-week study period, participants were issued with diary at the 
baseline study visit. 
 
We conducted a cost utility analyses which addresses health related quality of life.  NICE in England 
has recommended the use of quality-adjusted life years (QALYs) as the measure of health benefit for 
economic analysis as it allows comparisons across different clinical conditions, unlike condition 
specific quality of life measures [23].  We estimated costs from a NHS and from the NHS and patient 
perspective. We micro-costed NHS  secondary care resource  use in terms of the intervention and 
staff time spent with the participant  via a healthcare personal proforma completed at baseline and 
16 weeks follow up. Costs to participants in terms of out of pocket expenses and travel costs were 
estimated by a health economics patient self-completed proforma at baseline and 16 weeks. We 
derived unit costs of these sources from various sources [24] for podiatrists time (unit cost per 
minute for Band 5: 0.53). We obtained the costs of the foot orthoses (unit cost: £ 68.32) and the 
simple insole (unit cost of £24.82) to the NHS from Langer UK Ltd. Out of pocket and travel expenses 
incurred by participants were inflated to 2015 prices using the retail price index [25].  
 
We estimated the effects on health related quality of life (utilities) of the interventions and 
undertook a cost-utility analysis using QALYs as the measure of effect.  We estimated participant 
utilities by administering the EQ5D instrument [26] at baseline and 16 weeks; combined them with 
the area under the curve method to calculate QALY gains over the 16 week study period; and 
corrected for baseline EQ5D.  We estimated the cost per QALY gain by dividing differences in cost by 
differences in QALYs and compared by the thresholds recommended by NICE [23].    
  
Data Analysis 
We analysed data in SPSS version 22.0 (SPSS Inc., Chicago II, USA) and MS Excel 2010 (Microsoft 
Corporation, Redmond, Washington DC, USA). Results were reported according to the CONSORT 
statement [27]. All descriptive data and health status measurements were obtained at baseline and 
16 weeks. All participant data was included in the final data analysis to ensure continuity of balance 
in both arms of the trial to reduce bias. All data was subjected to tests for accuracy and quality 
before analysis was undertaken. No transformation of data was undertaken.  Differences between 
the two arms were determined by analysis of covariance (ANCOVA), to assess the impact of the two 
different FO interventions on participants’ scores across the time periods of the trial. Where 
appropriate, as when dealing with categorical data, non-parametric tests such as Mann Whitney U 
tests were used. R (R-Foundation for Statistical Computing, Vienna, Austria) and Statistical Analysis 
Software (SAS Institute Inc) using the sub-heading Proc Mixed for the ANCOVA. Differences between 
and within arms were presented as mean differences and 90% confidence intervals (90%CI). This has 
been recommended as an appropriate confidence level and also as a way of discouraging 
reinterpretation of the 90%CI as significant or non-significant at the 5% level [28]. Because of the 
small numbers of participants in our trial we performed boot-strapped t-tests to estimate the 
differences between utilities at each of the three time points and report means and standard 
deviations of the boot-strapped samples. To estimate effects on QALYS, we performed a linear 
regression with QALY gain as the dependent variable with treatment arm and baseline utility as 
independent variables. The level of statistical significance was set at 0.05. 
 
RESULTS 
One hundred and twenty participants were identified as potential participants in the study and forty-
one participants were randomised. The majority of participants were females (n=28, 68%) with a 
mean (SD) of 62 (10) years old and a mean (SD) disease duration of 14 (9) years. All participants were 
receiving NSAIDS (n = 36, 88%) and DMARDS (n = 37, 90%). At baseline, 20 participants received the 
CMFO and 21 participants received the SI. At 16 weeks, 75% (n=15) of participants in the CMFO-arm 
and 66% (n= 14) participants in the SI-arm completed the study. Twelve participants (29%) withdrew 
over the course of the study (Figure 1).  
 Table 1 demonstrates the descriptive statistics for the Foot Function Index domains. All participants 
wore their FOs when attending for review and reported wearing them in the week prior to review. 
The two interventions were worn on average 77 hours/week (CMFO-arm with an average of 87 
hours and the SI-arm an average of 67 hours). Three participants reported initial fit problems related 
to the thickness of the shoe insert, two withdrawing and one continuing within the trial after 
modifying footwear to increase the depth to accommodate the CMFO. No other adverse reactions 
were recorded. There was no difference between the two arms in wearing times over the 16 weeks 
(p=0.60). Table 2 demonstrates the differences between the sub-domains of the Foot Function Index 
from baseline to 16 weeks. The pain score reduced significantly in both intervention arms (p<0.000). 
The treatment effect of the intervention at 16 weeks was not significant between the two arms (p = 
0.14). The reduction in foot disability score was significant in the CMFO arm (p<0.000), but not in the 
SI arm (p =0.40). The treatment effect at 16 weeks did not reach significance (p = 0.12). The change 
in the activity limitation score did not reach significance in both arms (p<0.05).   
 
The effects of the interventions on health related quality of life (utility) and QALYs are shown in 
Table 3. At baseline there was a, statistically insignificant difference between the arms of the trial.  
The difference in baseline utility was 0.10 in favour of the CFMO-arm.  The CFMO-arm showed a 
decrease in utility at 16 weeks compared to baseline whereas the SI-arm showed an increase.  When 
the area under the curve controlling for baseline utility method was applied, there was small 
statistically insignificant QALY loss associated with the CFMO intervention compared to SI. Therefore 
there no statistically significant effect of the intervention on QALYs was found. 
 
The frequency of podiatric staff time was similar for both interventions at baseline and both follow-
up periods (Table 4).  Across the two-arms of the trial, the only significant difference in costs was 
that the CFMO being more expensive than the SI with a mean difference of £8.53 (bootstrapped 90% 
CI: £8.53 to £8.53). This lead to a statistically significant difference in total costs to the NHS with a 
mean difference of £8.90 (bootstrapped 90% CI: £5.02 to £13.27).  The mean costs of resource use 
over the 16 week follow-up period are illustrated in Table 5. The mean health gain, expressed as a 
difference in mean QALYs between interventions over the 16 week follow-up period, was -0.03 and 
the difference in mean cost to the NHS was £8.90.  From either costing perspective (NHS alone or 
NHS & patient), the CFMO was both more expensive and less effective than the SI and is therefore 
dominated.  
 
 
DISCUSSION 
NICE have suggested that interventions delivering a cost per QALY of under £20,000 are likely to be 
an acceptable use of NHS resources [17]. The current findings support the notion that foot orthoses 
for people with established RA delivers a cost-effective intervention. In both arms, from the societal 
perspective, patients’ costs were approximately equal and no further sensitivity analysis was 
undertaken. The cost per QALY gain results found in this study would suggest that the average cost 
per QALY gain is less than the NICE threshold and is therefore, an acceptable use of NHS resources. 
The main analysis was undertaken using only 16 weeks data, although it is likely that any benefits 
achieved within this period would be maintained for a longer period of time. It is plausible that 
changes in costs could have occurred over a longer time frame than the 16-week period, but this is 
an assumption without evidence therefore it was considered reasonable to assume equally 
distributed costs for this study. Both arms also only showed minimal improvement over the course 
of the study, but this may reflect a lack of sensitivity of the EQ5D to pick up subtle disease changes in 
the RA foot, which may have been masked by overall disease activity. 
 
We did find that pain scores improved significantly in both the arms, with a significant improvement 
in both the disability domain and total Foot Function Index scores for the CMFO-arm.  We found that 
there is a significant difference in cost between the two arms. The major difference in cost between 
the two arms maybe explained in terms of manufacturing time and costs of materials used in the 
manufacturing process with the CMFO costing significantly more to produce. However, the CMFO 
only produced some benefit in terms of patient outcomes. From a cost effectiveness analysis 
perspective the CMFO evaluated were far more expensive to manufacture, with the CMFO being 
£52.60 more expensive than the SI from an NHS perspective and £80.00 more expensive from an 
NHS and societal perspective. The CMFO may therefore be considered unlikely to be cost effective in 
comparison with the SI in the treatment of this cohort of RA patients of more than 2 years duration 
with foot pain, although still an acceptable use of healthcare resources overall. This does contrast 
with the cost-effectiveness study by Rome [16] which found that semi-rigid prefabricated foot 
orthoses resulted in a better quality of life for patients with plantar heel pain, despite being more 
expensive. It is, however, difficult to make any further comparisons with this study as the participant 
arm investigated was heterogeneous. The current study should therefore call into question the use 
of CMFO in preference to SIs in people with established RA, although further research would be 
needed to make any definitive recommendations. 
The current findings do present ramifications for health care professionals prescribing foot orthoses 
in people with established RA. A technology appraisal of foot orthoses has also not yet been 
undertaken by NICE, and although both interventions are likely to both deliver a cost per QALY of 
under £20,000 this finding does indicate that further research is necessary to support the 
prescription of foot orthoses in this cohort of patients as being  both cost and clinically effective. The 
sample size used for this study also limits validity as modelling was unable to be undertaken as a 
result, but as there is limited economic studies to draw upon in foot orthoses evidence which can 
knowledgably inform public health policy either locally or nationally. The current study relates to 
people with established RA, therefore future work could include cost effectiveness studies 
evaluating to the use of foot orthoses with early RA or in other inflammatory conditions. The current 
study was also undertaken using participants from the North-East of England, and therefore cannot 
be generalizable to all people with established RA. This study looked at the cost analysis of CMFO 
and SI and did not consider prefabricated foot orthoses. A larger clinical trial could be undertaken to 
investigate the cost effectiveness of simple insoles in people with established RA and further 
investigation into the cost effectiveness of foot orthoses in people with early RA.  
 
CONCLUSION 
The exploratory trial was novel as it has undertaken the cost effectiveness evaluation of the use of 
customised foot orthoses and simple insoles in people with established RA. Future research should 
be undertaken to evaluate the cost effectiveness of these devices in large scale studies involving 
both newly diagnosed and established people with RA, clearly defining the different types of foot 
orthoses to investigate and within different disease durations, with the aim to make 
recommendations regarding clinical provision and an acceptable cost ratio to provide foot orthoses. 
This will further inform health care professionals but may also stimulate discussion at higher levels 
and highlight the need for policy makers such as NICE to undertake Technology Appraisals and 
further assess interventions which are less invasive. 
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Table 1: Descriptive statistics for the Foot Function Index domains  
Variables Custom Made Foot Orthoses  
Mean (SD) 
Simple Insoles  
Mean (SD) 
Foot Pain 
Baseline 
16 weeks 
 
54.2 (14.2) 
30.8 (22.1) 
 
54.7 (23.4) 
41.3 (17.9) 
Foot Disability 
Baseline 
16 weeks 
 
53.3 (21.5) 
38.8 (24.2) 
 
51.1 (19.0) 
33.7 (27.1) 
Functional Limitation  
Baseline 
16 weeks 
 
28.2 (25.3) 
22.8 (17.4) 
 
17.8 (11.8) 
17.4 (11.7) 
 
    
 
Table 2: Differences of Foot Function Index sub-domains from baseline to 16 weeks 
Variables Mean Difference between baseline and 16 
weeks (90%CI) 
P 
Foot Pain 
Custom Made Foot Orthoses  
Simple Insole  
Treatment effect  
 
-23.1 (-30.9 to -15.2) 
-12.9 (-21.0 to -4.8) 
-10.2 (-21.5 to 1.3) 
 
<0.000 
0.01 
0.14 
Foot Disability 
Custom Made Foot Orthoses  
Simple Insole  
Treatment effect  
 
-16.3 (-25.8 to -6.9) 
-3.9 (-12.9 to 5.2) 
-12.4 (-25.5 to 0.6) 
 
0.00 
0.40 
0.12 
Functional Limitation 
Custom Made Foot Orthoses 
Simple Insole  
Treatment effect 
 
-1.1 (-6.5 to 4.4) 
0.2 (6.4 to -6.8) 
-1.3 (-10.0 to -7.4) 
 
0.74 
0.95 
0.80 
 
 
  
 
 
Table 3: EQ5D utility index at baseline and 16 weeks  
Outcome Bootstrapped Mean 
(SD) 
Estimated Difference.  Adjusted for 
Baseline  (90% CI) 
P 
 Custom 
Made 
Foot 
Orthoses 
Simple 
Insole 
  
Baseline 
utility 
0.59 
(0.07) 
0.49 
(0.32) 
0.10 (-0.08 0.26)  0.34 
16 
Weeks 
utility 
0.57 
(0.28) 
0.56 
(0.22) 
0.01 (-0.15 0.14)  0.94 
QALY 0.04 
(0.10) 
0.00 
(0.10) 
 -0.03 (-0.08 0.03)  0.46 
 
 
 Table 4:  Mean NHS Resource Use 
Podiatrist Time Spent with 
Participant (minutes)  
Custom Made Foot Orthoses  
Mean (SD) 
Simple Insole 
Mean(SD) 
Time spent at baseline 24 (5) 23(7) 
Time spent at 16 weeks 20 (8) 20 (3) 
 
 Table 5:  Mean cost of resource use (£) over the 16 week follow-up period 
Resource Use Custom Made 
Foot Orthoses 
Mean (SD)  
Simple Insole 
Mean (SD)  
Mean difference (90% CI 
bootstrapped) 
Cost of intervention 33.35 (0) 24.82 (0) 8.53 (8.53,8.53) 
Total podiatrists time 33.25 (7) 32.78 (7) 0.46 (-3.54, 4.70) 
Total costs of 
equipment purchased 
by participants  
20.24 (47.46) 9.38 (25.30) 10.85 (-10.40, 35.79) 
Total costs of journeys 11.21 (9.52) 7.45 (6.15) 3.76 (-0.60, 8.77) 
Total Costs to 
participants 
31.45 (50.15) 16.86 (28.02) 14.62 (-8.27,40.53) 
Total Costs to the NHS 
(podiatrists time plus 
intervention cost) 
76.56 (7.07) 67.66 (6.75) 8.90 (4.78,13.39) 
Total costs to the NHS 
and participants 
108.01 (55.42) 84.50(29.30) 23.52(-1.67,50.94) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 1: CONSORT flow chart 
